
Aclaris Therapeutics, Inc.: updates and filings
Price
$3.44
November 20, 2026Market cap $546M
What Ploutos Investor adds for Aclaris Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 9 fiscal years, from 2017
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Regulation FD disclosure, other material eventsForm8-K
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operationsForm8-K
- Oct 27, 2026Material agreement enteredForm8-K
- Oct 27, 2026Results of operations, Regulation FD disclosure, other material eventsForm8-K
- Sep 21, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 6, 2026Material agreement enteredForm8-K
- Aug 6, 2026Shelf registration for future offeringsFormS-3ASR
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jun 4, 2026Shareholder voteForm8-K
- May 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operationsForm8-K
- Apr 28, 2026Regulation FD disclosure, other material eventsForm8-K
- Apr 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 23, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 23, 2026Additional annual meeting materialFormDEFA14A
- Apr 23, 2026Annual meeting proxy statementFormDEF 14A
- Apr 7, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 17, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Mar 11, 2026Regulation FD disclosureForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations | Document |
| Oct 27, 2026 | 8-K | Material agreement entered | Document |
| Oct 27, 2026 | 8-K | Results of operations, Regulation FD disclosure, other material events | Document |
| Sep 21, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 6, 2026 | 8-K | Material agreement entered | Document |
| Aug 6, 2026 | S-3ASR | Shelf registration for future offerings | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jun 4, 2026 | 8-K | Shareholder vote | Document |
| May 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| Apr 28, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Apr 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 23, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 23, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 23, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 7, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 17, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Mar 11, 2026 | 8-K | Regulation FD disclosure | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Sep 10, 2012.
The full analysis
What do Aclaris Therapeutics's filings show?
The filings are where every one of Aclaris Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.